APA (7th ed.) Citation

RI, J., MA, F., J, H., J, W., MW, K., DC, B., . . . SC, G. (2016). Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: A randomized open-label study. Journal of neuro-oncology, 129(1), 131. https://doi.org/10.1007/s11060-016-2155-4

Chicago Style (17th ed.) Citation

RI, Jakacki, Foley MA, Horan J, Wang J, Kieran MW, Bowers DC, Bouffet E, Zacharoulis S, and Gill SC. "Single-agent Erlotinib Versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma: A Randomized Open-label Study." Journal of Neuro-oncology 129, no. 1 (2016): 131. https://doi.org/10.1007/s11060-016-2155-4.

MLA (9th ed.) Citation

RI, Jakacki, et al. "Single-agent Erlotinib Versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma: A Randomized Open-label Study." Journal of Neuro-oncology, vol. 129, no. 1, 2016, p. 131, https://doi.org/10.1007/s11060-016-2155-4.